What we do

isoSolutions Marketing & Management Inc. offers a wide range of products for nuclear medicine applications, from a variety of reliable suppliers, providing a one-stop shopping service as well as technical support.


David T. Drummond Managing Director

People matter the most. Every organization should aim to leave people better off. In the health sector that starts with the patient but must also include our suppliers, customers, employees, partners – indeed, everyone whose life is touched by our company.


Companies connected
through isoSolutions


Products sold
worldwide in 2016


Orders delivered
on time in 2016


First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera

Kevin Yang ⎜ Mar 20, 2018

99mTc-sestamibi CZT-SPECT is technically feasible and can provide similar result to 15O-water PET for detecting impaired myocardial flow reserve and abnormal fractional flow reserve in patients with coronary artery disease. This study highlights the diagnostic value of using 99mTc -sestamibi for patients with coronary artery disease.

The WATERDAY study: Denis Agostini & Vincent Roule & Catherine Nganoa & Nathaniel Roth & Raphael Baavour & Jean-Jacques Parienti & Farzin Beygui & Alain Manrique

Info on purchasing 99mTc -sestamibi, contact sales@isosolutions.com

For more info on this article, please click here.

keep reading

Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation

David T. Drummond ⎜ Mar 14, 2018

During the last decade, the utilization of 68Ga for the development of imaging agents has increased considerably with the leading position in the oncology. The imaging of infection and inflammation is lagging despite strong unmet medical needs. This review presents the potential routes for the development of 68Ga-based agents for the imaging and quantification of infection and inflammation in various diseases and connection of the diagnosis to the treatment for the individualized patient management.


The medical need for specific agents for noninvasive, quantitative, and whole-body imaging of inflammation and infection has not been met yet despite decades of research. However, the prerequisites in terms of identification of potential targets, design and synthesis of the respective ligands, and imaging technologies are evolving very fast. The potential of accurate and quantitative lesion localization as well as monitoring of the treatment response promises personalized patient management.

The use of 68Ga in oncology is established proving the strong potential of 68Ga for the promotion of PET technology for effective and efficient diagnostics and personalized medicine. The experience of oncological 68Ga-based agents is getting translated to inflammation and infection. Pretargeted imaging technology opens wide possibilities based on antibody biomarkers.

Contrast Media & Molecular Imaging
Volume 2018 (2018), Article ID 9713691, 24 pages

Copyright © 2018 Irina Velikyan

More about this article here: https://www.hindawi.com/journals/cmmi/2018/9713691/

keep reading


Jun 23 to 26

Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2018

Pennsylvania Convention Center, Headquarter Hotel: Philadelphia Marriott. isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Mar 23 to 24

Canadian Nuclear Medicine Scientific Meeting 2018

isoSolutions will be present at the Canadian Nuclear Medicine Annual Scientific Meeting in Vancouver, BC from 2018–03–23 to 2018–03–24.

Nov 3 to 5

The 2017 Western Region SNMMI Annual Meeting

isoSolutions is pleased to inform you that we will exhibit at the 2017 Western Region Society of Nuclear Medicine Annual Meeting held at the Westin BayShore in Vancouver, British Columbia from 2017–11–03 to 2017–11–05. We hope to see you there and we can arrange a time and place to meet if you wish.